Search

Displaying results 4051 - 4060 of 6951 in total
  1. Drug

    Phenazopyridine

    go.drugbank.com/drugs/DB01438
    ApprovedInvestigational

    Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during

  2. Drug

    NRP290

    go.drugbank.com/drugs/DB06383
    Experimental

    NRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).

  3. Drug

    Pafuramidine

    go.drugbank.com/drugs/DB06532
    Investigational

    Pafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.

  4. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  5. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  6. Drug

    Pantethine

    go.drugbank.com/drugs/DB11190
    Approved

    Pantethine is available as a dietary supplement for lowering blood cholesterol and triglycerides.

  7. Drug

    Thimerosal

    go.drugbank.com/drugs/DB11590
    Approved

    Thiomersal (INN), commonly known in the U.S. as thimerosal, is an organomercury compound. This compound is a well-established and widely used antiseptic and antifungal agent. Developed in 1927, thimerosal has been and is still being used...

  8. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. … It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.

  9. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes.

  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).